Latest Kidney Cancer News
Kidney Cancer News elsewhere on the Web
The prospective, multicentre, open-label trial is set to begin in the second half of this year.
A genitourinary oncologist discusses current treatment options available for patients with non–clear cell renal cell carcinoma and discusses the roles of tyrosine kinase inhibitors (TKIs), PD-1 inhibition, and combination therapy.
Martin H. Voss, MD, and Moshe Ornstein, MD, engage in a professional discourse concerning the current treatment standards and the evolving therapeutic landscape for non-clear cell renal cell carcinoma (RCC).
Phillip Koo interviews Shankar Siva about advancements in functional renal imaging. Dr. Siva discusses the current standard imaging for localized kidney cancer, which includes triple-phase CT or MRI with IV contrast, and the limitations of bone scans for detecting metastases. He highlights the ...
Sunitinib has greatly improved the survival of clear cell renal cell carcinoma (ccRCC) patients in recent years. However, 20–30% of treated patients do not respond. To identify miRNAs and genes associated with a response, comparisons were made between biopsies from responder and non-responder ...
In this Review, the authors discuss advantages and complications associated with renal mass biopsy and provide an overview of different features of both well-recognized types of renal cell carcinoma and newly identified subtypes to improve diagnosis and management.
Michael Serzan, MD, discusses the use of botensilimab/balstilimab in the treatment of patients with advanced renal cell carcinoma.
Subcutaneous nivolumab is also under review in the United States based on findings from the phase 3 CheckMate-67T trial.
Lipid droplet formation is a prominent histological feature in clear cell renal cell carcinoma (ccRCC), but the significance and mechanisms underlying lipid droplet accumulation remain unclear. Expression and clinical significance of MT1G in ccRCC were analyzed by using TCGA data, GEO data and ...
The European Medicines Agency will begin a centralized review process for subcutaneous nivolumab across multiple solid tumor indications.
No results found.
Articles from Kidney Cancer UK
No results found.
No results found.